DT-9046 / Kainova Therapeutics - LARVOL DELTA

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies (GlobeNewswire) - "Lead asset DT-7012, a Treg-depleting anti-CCR8 antibody, is progressing in the ongoing Phase I/II DOMISOL trial for the treatment of solid tumors. The Company is also advancing other GPCR-targeting therapies, including DT-9081, an EP4 antagonist for solid tumors and DT-9046, a small molecule biased antagonist of PAR2 for inflammatory conditions, further positioning Kainova Therapeutics as a leader in global precision medicine."

Financing • Inflammation • Solid Tumor

Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for Inflammatory Diseases (PRNewswire) - "Domain Therapeutics...today announces it has nominated and is progressing DT-9046, a candidate with game-changing potential in multiple inflammatory disease markets, including atopic dermatitis (AD), inflammatory bowel disease (IBD), arthritis but also neuroinflammation including migraine....DT-9046 is currently progressing through pre-IND studies, supported by a robust data package and strong patent protection. Preclinical studies have demonstrated potent and selective modulation of the immune response, which plays a crucial role in various inflammatory conditions, particularly in AD and IBD."

Pipeline update • Preclinical • Atopic Dermatitis • Inflammatory Bowel Disease • Migraine